🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

399 results for “Pari” Clear

  1. Heparin

    China SXT Pharmaceuticals

    Thromboprophylaxis

    phase 2 small molecule active

    1 trial

  2. Heparin and Rivaroxaban

    First Tracks Biotherapeutics

    Liver Cirrhosis

    phase 2 small molecule completed

    1 trial

  3. ILT-101 liquide, Placebo of ILT-101

    Pari Pharma GmbH

    Autism Spectrum disorder ASD

    phase 2 small molecule active

    1 trial

  4. ILT-101 liquide, Placebo of ILT-101, CICLOSPORIN

    Pari Pharma GmbH

    Patient with newly diagnosed (≤ 3 months) type 1 diabetes stage 3

    phase 2 small molecule active

    1 trial

  5. IMFINZI 50 mg/mL concentrate for solution for infusion., TREMELIMUMAB

    Pari Pharma GmbH

    Hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  6. INFLIXIMAB , TOCILIZUMAB , Cosentyx 300 mg solution for injection in pre-filled pen, ADALIMUMAB

    Pari Pharma GmbH

    TAkayasu ARteritiS

    phase 2 small molecule active

    1 trial

  7. INFLIXIMAB, RoActemra 20 mg/mL concentrate for solution for infusion

    Pari Pharma GmbH

    Takayasu arteritis

    phase 2 small molecule active

    1 trial

  8. INTERFERON GAMMA , TOCILIZUMAB , DALTEPARIN , HEPARIN , BARICITINIB, FLUDROCORTISONE , HYDROCORTISONE, OCTAPLASLG, solution pour perfusion, BARICITINIB, ANAKINRA , FILGRASTIM

    Pari Pharma GmbH

    Sepsis

    phase 2 small molecule active

    1 trial

  9. ISATUXIMAB

    Pari Pharma GmbH

    Isatuximab in type I cryoglobulinaemia: A prospective pilot study

    phase 2 small molecule active

    1 trial

  10. Intensity-modulated radiation therapy (IMRT) in combination with fluzoparib, abiraterone acetate tablets (II), and prednisone.

    China SXT Pharmaceuticals

    Metastatic Castration-resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  11. Itacitinib

    Pari Pharma GmbH

    Adults patients having non severe HLH

    phase 2 small molecule active

    1 trial

  12. Itacitinib, placebo of itacitinib 100mg

    Pari Pharma GmbH

    Patients with newly or active diffuse Systemic sclerosis (SSc) at the time of screening

    phase 2 small molecule active

    1 trial

  13. Jakavi 15 mg tablets, Jakavi 5 mg tablets, Jakavi 10 mg tablets, Jakavi 20 mg tablets

    Pari Pharma GmbH

    haemophagocytic lymphohistiocytosis (HLH) in children

    phase 2 small molecule active

    1 trial

  14. Jakavi 15 mg tablets, Placebo of Jakavi 15mg

    Pari Pharma GmbH

    Inclusion body Myositis

    phase 2 small molecule active

    1 trial

  15. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, Olaparib

    Fondazione Telethon ETS

    Adult patients affected by recurrent/metastatic, platinum resistant nasopharyngeal cancer

    phase 2 small molecule active

    1 trial

  16. LENVIMA 4 mg hard capsules

    Pari Pharma GmbH

    Non-resectable hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  17. LENVIMA 4 mg hard capsules

    Pari Pharma GmbH

    Patients with Biopsy-proven or radiologically-suggested BCLC A HCC eligible for PA and comprising at least one of the following criteria: - Single tumour>3 cm≤ 5cm or - multiple tumours (max 3 lesions ≤ 3cm) or - Single tumour between 2 and 3 cm with at least one of the following characteristic: • Serum AFP>100 ng/mL • Infiltrative form • Macro-trabecular subtype (if applicable)

    phase 2 small molecule active

    1 trial

  18. Low Molecular Weight Heparin (LMWH)

    Cardiff Oncology

    Cancer

    phase 2 small molecule terminated

    1 trial

  19. Luminity 150 microlitres/ml gas and solvent for dispersion for injection/infusion, TEMOZOLOMIDE , LOMUSTINE

    Pari Pharma GmbH

    Newly diagnosed Glioblastoma (IDH wild-type) patients at initial radiological diagnosis eligible for tumor resection, and for the standard of care including concurrent temoradiation followed by adjuvant TMZ with or without Tumor Treating Fields*. (*Tumor Treating Fields is applicable only in participating centers in France)

    phase 2 small molecule active

    1 trial

  20. METFORMIN , Placebo 515

    Pari Pharma GmbH

    Portal hypertension (PHT) and consequences in complications of cirrhosis

    phase 2 small molecule active

    1 trial

  21. METHYLPREDNISOLONE, METHYLPREDNISOLONE, IMMUNOGLOBULINS, NORMAL HUMAN, FOR INTRAVASCULAR ADM., GLUCOSE 5 % B.BRAUN, solution pour perfusion

    Pari Pharma GmbH

    Fulminant myocarditis

    phase 2 small molecule active

    1 trial

  22. METHYLPREDNISOLONE, METHYLPREDNISOLONE, METHYLPREDNISOLONE HYDROGEN SUCCINATE, METHYLPREDNISOLONE , METHYLPREDNISOLONE, METHYLPREDNISOLONE, METHYLPREDNISOLONE

    Pari Pharma GmbH

    NEUROENDOCRINE CELLS HYPERPLASIA OF INFANCY

    phase 2 small molecule active

    1 trial

  23. MOVIPREP, MaaT033, MOVIPREP Orange, poudre pour solution buvable, Placebo is an inert coated capsule with no microbiota (active substance) inside. It is composed of a mix of coloring agents and partially pre-gelatinized corn starch in Hydroxypropyl methylcellulose capsule.

    Pari Pharma GmbH

    AXIAL SPONDYLOARTHRITIS

    phase 2 small molecule active

    1 trial

  24. MSCAT-THAC Placebo, Allogeneic Mesenchymal stromal cells derived from adipose tissue thawed and cultured

    Pari Pharma GmbH

    Systemic sclerosis

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources